OncoMatch/Clinical Trials/NCT05530655
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
Is NCT05530655 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Lisinopril Tablets for prostate cancer.
Treatment: Lisinopril Tablets — This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: pelvic radiotherapy
Lab requirements
Blood counts
hemoglobin ≥9.0 g/dL, independent of transfusion and/or growth factors; platelet count ≥100,000/µL independent of transfusion and/or growth factors
Kidney function
creatinine clearance > 30 mL/min within 30 days prior to registration
Liver function
hepatic function deemed adequate for planned treatment by the treating investigator within 90 days prior to registration
Have adequate renal function with creatinine clearance > 30 mL/min within 30 days prior to registration; Have hematologic and hepatic function deemed adequate for planned treatment by the treating investigator within 90 days prior to registration, including: hemoglobin ≥9.0 g/dL, independent of transfusion and/or growth factors; platelet count ≥100,000/µL independent of transfusion and/or growth factors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wilmot Cancer Institute · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify